The use of recombinant factor VIIa in warfarin patients with traumatic brain injury

A retrospective case-control study

Emma P. Deloughery, Barbara Lenfesty, Thomas Deloughery

    Research output: Contribution to journalArticle

    6 Citations (Scopus)

    Abstract

    Patients on warfarin who have traumatic intracranial haemorrhage have a high mortality. The procoagulant recombinant factor VIIa (rFVIIa) is widely used off-label to treat intracranial haemorrhaging in patients taking warfarin to try to improve these adverse outcomes, but its effectiveness is unknown. In this study, medical records from 2002 to 2010 were reviewed for 27 warfarin patients who received rFVIIa for their traumatic intracranial haemorrhage and were compared with a matched control group of 27 warfarin patients who did not receive rFVIIa. The two groups were matched for sex, age and Injury Severity Score. The rFVIIa patients had 33.3% mortality compared with the 37% for the control patients, but this was not a statistically significant difference. There was also no significant difference in plasma unit use between the groups. However, the rFVIIa group had a significantly higher number of subdural haemorrhages, which carry a better prognosis. The initial international normalized ratios (INRs) of the rFVIIa patients were higher, and the decrease of INR was more pronounced than in the control patients. From the data, it appears that although the INRs of rFVIIa patients did improve compared with the control group, there was no reduction in plasma use or mortality.

    Original languageEnglish (US)
    Pages (from-to)317-320
    Number of pages4
    JournalBlood Coagulation and Fibrinolysis
    Volume24
    Issue number3
    DOIs
    StatePublished - Apr 2013

    Fingerprint

    Warfarin
    Case-Control Studies
    International Normalized Ratio
    Traumatic Intracranial Hemorrhage
    Mortality
    Research Design
    Traumatic Brain Injury
    recombinant FVIIa
    Subdural Hematoma
    Control Groups
    Injury Severity Score
    Medical Records

    Keywords

    • intracranial haemorrhage
    • plasma
    • recombinant factor VIIa
    • warfarin

    ASJC Scopus subject areas

    • Hematology

    Cite this

    The use of recombinant factor VIIa in warfarin patients with traumatic brain injury : A retrospective case-control study. / Deloughery, Emma P.; Lenfesty, Barbara; Deloughery, Thomas.

    In: Blood Coagulation and Fibrinolysis, Vol. 24, No. 3, 04.2013, p. 317-320.

    Research output: Contribution to journalArticle

    @article{464798a6bd5742b9af311e9541cfcc88,
    title = "The use of recombinant factor VIIa in warfarin patients with traumatic brain injury: A retrospective case-control study",
    abstract = "Patients on warfarin who have traumatic intracranial haemorrhage have a high mortality. The procoagulant recombinant factor VIIa (rFVIIa) is widely used off-label to treat intracranial haemorrhaging in patients taking warfarin to try to improve these adverse outcomes, but its effectiveness is unknown. In this study, medical records from 2002 to 2010 were reviewed for 27 warfarin patients who received rFVIIa for their traumatic intracranial haemorrhage and were compared with a matched control group of 27 warfarin patients who did not receive rFVIIa. The two groups were matched for sex, age and Injury Severity Score. The rFVIIa patients had 33.3{\%} mortality compared with the 37{\%} for the control patients, but this was not a statistically significant difference. There was also no significant difference in plasma unit use between the groups. However, the rFVIIa group had a significantly higher number of subdural haemorrhages, which carry a better prognosis. The initial international normalized ratios (INRs) of the rFVIIa patients were higher, and the decrease of INR was more pronounced than in the control patients. From the data, it appears that although the INRs of rFVIIa patients did improve compared with the control group, there was no reduction in plasma use or mortality.",
    keywords = "intracranial haemorrhage, plasma, recombinant factor VIIa, warfarin",
    author = "Deloughery, {Emma P.} and Barbara Lenfesty and Thomas Deloughery",
    year = "2013",
    month = "4",
    doi = "10.1097/MBC.0b013e32835cc16b",
    language = "English (US)",
    volume = "24",
    pages = "317--320",
    journal = "Blood Coagulation and Fibrinolysis",
    issn = "0957-5235",
    publisher = "Lippincott Williams and Wilkins",
    number = "3",

    }

    TY - JOUR

    T1 - The use of recombinant factor VIIa in warfarin patients with traumatic brain injury

    T2 - A retrospective case-control study

    AU - Deloughery, Emma P.

    AU - Lenfesty, Barbara

    AU - Deloughery, Thomas

    PY - 2013/4

    Y1 - 2013/4

    N2 - Patients on warfarin who have traumatic intracranial haemorrhage have a high mortality. The procoagulant recombinant factor VIIa (rFVIIa) is widely used off-label to treat intracranial haemorrhaging in patients taking warfarin to try to improve these adverse outcomes, but its effectiveness is unknown. In this study, medical records from 2002 to 2010 were reviewed for 27 warfarin patients who received rFVIIa for their traumatic intracranial haemorrhage and were compared with a matched control group of 27 warfarin patients who did not receive rFVIIa. The two groups were matched for sex, age and Injury Severity Score. The rFVIIa patients had 33.3% mortality compared with the 37% for the control patients, but this was not a statistically significant difference. There was also no significant difference in plasma unit use between the groups. However, the rFVIIa group had a significantly higher number of subdural haemorrhages, which carry a better prognosis. The initial international normalized ratios (INRs) of the rFVIIa patients were higher, and the decrease of INR was more pronounced than in the control patients. From the data, it appears that although the INRs of rFVIIa patients did improve compared with the control group, there was no reduction in plasma use or mortality.

    AB - Patients on warfarin who have traumatic intracranial haemorrhage have a high mortality. The procoagulant recombinant factor VIIa (rFVIIa) is widely used off-label to treat intracranial haemorrhaging in patients taking warfarin to try to improve these adverse outcomes, but its effectiveness is unknown. In this study, medical records from 2002 to 2010 were reviewed for 27 warfarin patients who received rFVIIa for their traumatic intracranial haemorrhage and were compared with a matched control group of 27 warfarin patients who did not receive rFVIIa. The two groups were matched for sex, age and Injury Severity Score. The rFVIIa patients had 33.3% mortality compared with the 37% for the control patients, but this was not a statistically significant difference. There was also no significant difference in plasma unit use between the groups. However, the rFVIIa group had a significantly higher number of subdural haemorrhages, which carry a better prognosis. The initial international normalized ratios (INRs) of the rFVIIa patients were higher, and the decrease of INR was more pronounced than in the control patients. From the data, it appears that although the INRs of rFVIIa patients did improve compared with the control group, there was no reduction in plasma use or mortality.

    KW - intracranial haemorrhage

    KW - plasma

    KW - recombinant factor VIIa

    KW - warfarin

    UR - http://www.scopus.com/inward/record.url?scp=84875822627&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84875822627&partnerID=8YFLogxK

    U2 - 10.1097/MBC.0b013e32835cc16b

    DO - 10.1097/MBC.0b013e32835cc16b

    M3 - Article

    VL - 24

    SP - 317

    EP - 320

    JO - Blood Coagulation and Fibrinolysis

    JF - Blood Coagulation and Fibrinolysis

    SN - 0957-5235

    IS - 3

    ER -